Skip to main content
Clinical Trials/NCT02513524
NCT02513524
Completed
Not Applicable

The Prevalence of Pseudo-resistant Hypertension Using the Direct Observed Therapy Test: A Prospective Observational Study

Ottawa Hospital Research Institute1 site in 1 country60 target enrollmentSeptember 2015
ConditionsHypertension

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Hypertension
Sponsor
Ottawa Hospital Research Institute
Enrollment
60
Locations
1
Primary Endpoint
Prevalence of true resistant hypertension
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

High blood pressure is a risk factor for bad clinical events, such as heart failure, stroke, kidney failure and death. This risk is much higher in those with 'resistant' hypertension, in whom the blood pressure remains high despite more than 3 blood pressure medicines. Current estimates of the proportion of individuals with resistant hypertension may be an overestimate, since some of them are not actually adherent (i.e. not taking the medicines they are prescribed). Methods to detect non-adherence, such as asking the patient, counting pills, and getting records from pharmacy are not fool proof. Direct observed therapy (where patients are administered medicines under observation by a health care personnel) is quite useful to diagnose this, and is the standard of care in the Renal Hypertension Clinic, before more tests and interventions (such as CT scans, renal angiogram) are performed.

In this study, the investigators will measure the proportion of patients with resistant hypertension who are non-adherent based on direct observed therapy, and follow them up to examine the impact of this diagnosis.

Detailed Description

This is a prospective, observational study. Patients fitting inclusion and exclusion criteria, after informed consent, will undergo the direct observed therapy test in the hypertension unit (this is usual care in the unit, which they will undergo even if they are not part of the study). The Direct Observation Therapy (DOT) Test includes the following components: 1. Administer and observe ingestion of usual morning antihypertensive medications. 2. Monitor BP every 30 minutes, using 5 readings of an automated oscillometric BP device ( BP-TRU), until plateau affect achieved, defined as 3 consecutive cycles of BP readings declining by less than 10 mmHg per cycle). 3. Registered Nurse (RN) repeats standing BP prior to initiation of 24 hour Ambulatory Blood Pressure Monitoring(ABPM). 4. RN initiates 24 hour ABPM In addition, participants will undergo an additional 24-hour ABPM test 1 month after the DOT test is undertaken.

Registry
clinicaltrials.gov
Start Date
September 2015
End Date
September 2018
Last Updated
7 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age 18 years or older
  • Confirmed resistant hypertension defined as daytime BP readings above 135/85 mmHg (confirmed by 24-hour ABPM results) using 3 or more BP lowering drugs
  • Adherence to medications confirmed by patient, and by hypertension clinic on basis of pharmacy filling record

Exclusion Criteria

  • Pregnant patients
  • Inability to provide informed consent

Outcomes

Primary Outcomes

Prevalence of true resistant hypertension

Time Frame: 1 week

The proportion of patients who continue to have resistant hypertension after administration of direct observed therapy, on the basis of the 24 hour ambulatory testing

Secondary Outcomes

  • Prevalence of resistant hypertension at 1 month(1 month)

Study Sites (1)

Loading locations...

Similar Trials